DE69431880T2 - Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten - Google Patents

Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten

Info

Publication number
DE69431880T2
DE69431880T2 DE69431880T DE69431880T DE69431880T2 DE 69431880 T2 DE69431880 T2 DE 69431880T2 DE 69431880 T DE69431880 T DE 69431880T DE 69431880 T DE69431880 T DE 69431880T DE 69431880 T2 DE69431880 T2 DE 69431880T2
Authority
DE
Germany
Prior art keywords
imidazolin
amino
quinoxaline derivatives
quinoxaline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431880T
Other languages
English (en)
Other versions
DE69431880D1 (de
Inventor
James A Burke
Michael E Garst
Larry A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69431880D1 publication Critical patent/DE69431880D1/de
Publication of DE69431880T2 publication Critical patent/DE69431880T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69431880T 1993-10-13 1994-09-19 Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten Expired - Lifetime DE69431880T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13571693A 1993-10-13 1993-10-13
PCT/US1994/010569 WO1995010280A1 (en) 1993-10-13 1994-09-19 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Publications (2)

Publication Number Publication Date
DE69431880D1 DE69431880D1 (de) 2003-01-23
DE69431880T2 true DE69431880T2 (de) 2003-09-18

Family

ID=22469328

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431880T Expired - Lifetime DE69431880T2 (de) 1993-10-13 1994-09-19 Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten

Country Status (8)

Country Link
US (7) US5552403A (de)
EP (2) EP1285657A3 (de)
JP (3) JP3683908B2 (de)
AU (1) AU688380B2 (de)
CA (1) CA2173974C (de)
DE (1) DE69431880T2 (de)
ES (1) ES2187533T3 (de)
WO (1) WO1995010280A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO2000023066A2 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
AU720326B2 (en) 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
US6465713B1 (en) * 1997-06-30 2002-10-15 Mcneil-Ppc, Inc. Tampon having an apertured film cover
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
ES2392636T3 (es) 2000-07-14 2012-12-12 Allergan, Inc. Composiciones que contienen componentes terapéuticamente activos que tienen solubilidad mejorada
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
ES2332049T5 (es) 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
WO2005039567A1 (en) * 2003-10-08 2005-05-06 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
DE102004024011A1 (de) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluorbenzo-1,3-dioxole
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
US7926280B2 (en) * 2007-05-16 2011-04-19 Pratt & Whitney Canada Corp. Interface between a combustor and fuel nozzle
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US8293742B2 (en) * 2008-08-01 2012-10-23 Alpha Synergy Development, Inc. Preferential vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
EP2329849B1 (de) 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117377A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
ES2730411T3 (es) 2010-03-26 2019-11-11 Galderma Res & Dev Composiciones mejoradas que comprenden brimonidina para un tratamiento seguro y eficaz de la telangiectasia
EP2555750A2 (de) 2010-04-07 2013-02-13 Allergan, Inc. Kombinationen aus konservierungsstoffzusammensetzungen für ophthalmische formulierungen
US20110251285A1 (en) 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
BR112013009578B1 (pt) 2010-10-21 2020-10-20 Galderma S.A. composição tópica em gel e uso de uma composição tópica em gel
WO2013016178A1 (en) * 2011-07-25 2013-01-31 Allergan, Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
RU2014119879A (ru) 2011-10-19 2015-11-27 Галдерма С.А. Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230960C (de) *
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
US4188393A (en) * 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
US4656291A (en) * 1985-03-15 1987-04-07 Mcneilab, Inc. Process for producing amidine sulfonic acids
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5034406A (en) * 1989-09-26 1991-07-23 Allergan, Inc. Method for reducing or maintaining intraocular pressure
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives

Also Published As

Publication number Publication date
US5714486A (en) 1998-02-03
EP1285657A2 (de) 2003-02-26
JPH09506338A (ja) 1997-06-24
EP0723447B1 (de) 2002-12-11
AU7798894A (en) 1995-05-04
JP2005232186A (ja) 2005-09-02
CA2173974C (en) 2006-05-02
US5552403A (en) 1996-09-03
JP2003277264A (ja) 2003-10-02
JP3683908B2 (ja) 2005-08-17
WO1995010280A1 (en) 1995-04-20
US5587376A (en) 1996-12-24
CA2173974A1 (en) 1995-04-20
US5756503A (en) 1998-05-26
ES2187533T3 (es) 2003-06-16
EP1285657A3 (de) 2003-08-20
US5703077A (en) 1997-12-30
US5773440A (en) 1998-06-30
EP0723447A1 (de) 1996-07-31
US5561132A (en) 1996-10-01
DE69431880D1 (de) 2003-01-23
AU688380B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
DE69431880T2 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE59309479D1 (de) Verwendung von detergensgemischen
DE69418220T2 (de) Befestigung von Biomolekülen
DE69220382D1 (de) Verwendung von Peptidderivaten
DE69636313D1 (de) Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE706657T1 (de) Wechselwirkungen von inhibierungsproteinen
DE69626729D1 (de) Kombination von Datenwerten
KR960702737A (ko) 구강내-처치용 전극(intraoral-procedures electrode)
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE59209936D1 (de) Verwendung von Acetalen
DE69431201D1 (de) Verwendung von indolderivaten als 5ht1-agonisten
EE9400420A (et) Indenoindoolühendite kasutamine
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE68913397T2 (de) Verwendung von 5-heteroaryl- oder 5-arylsubstituierten Imidazo(2,1-a)isochinolinen.
DE69827393D1 (de) Kosmetische verwendung von bis-resorcinol-triazinderivaten
DE59508900D1 (de) Verwendung von Dibrom-thiophen-carbonsäure-Derivaten als Mikrobizide
DE59204051D1 (de) Verwendung von polymodalem beta-Oktogen.
DE59401861D1 (de) Verwendung von ferrocen
DE69711223T2 (de) Verwendung von cordia dichotoma extrakten
FI944280A0 (fi) Mingreenin vastaisia indolyylialkyyli-pyridinyyli- ja-pyrimidinyyli-piperatsiinien syklobuteenidionijohdannaisia
DE59403207D1 (de) Herstellung von Perfluoralkanen
NO931399D0 (no) Anvendelse av naturstein
DE69418676D1 (de) Deprotonierung von Cyclopentadienylderivate
DE59407338D1 (de) Verwendung von peroxogenierten Cycloolefincopolymeren
DE59308823D1 (de) Verwendung von Thioalkandionen als Aromastoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition